Rapport Therapeutics, Inc. RAPP

Biotech stocks widely slumped Wednesday, with Rapport Therapeutics, Climb Bio and Cullinan Therapeutics among some of the hardest-hit names.

BOSTON and SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that management plans to participate in the following upcoming investor events: Cantor Global Healthcare Conference (New York City) – fireside chat on Wednesday, September 9, 202

BOSTON and SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, September 22, 2026, at 12:30 PM ET. To register for the event, please click here. The event will feature lea

RAP-219 Phase 3 program in focal onset seizures initiated, with FOCUS 1 and FOCUS 2 trials enrolling patients RAP-219 Phase 2 trial in bipolar mania on track for topline results in October 2026 Pipeline continues to advance, including the RAP-219 long-acting injectable and primary generalized tonic-clonic seizures program, and the RAP-641 α6β4 nAChR program in chronic pain and migraine Ended the second quarter of 2026 with $436.1 million in cash, cash equivalents and short-term investments, excl

Is RAPP a good stock to buy? We came across a bullish thesis on Rapport Therapeutics, Inc. on TradersPro’s Substack. In this article, we will summarize the bulls’ thesis on RAPP. Rapport Therapeutics, Inc.’s share was trading at $38.26 as of June 15th. RAPP’s trailing P/E was 23.78 according to Yahoo Finance. Rapport Therapeutics (RAPP) is a […]

In late May 2026, analysts BTIG and Truist highlighted Rapport Therapeutics’ RAP-219 program after the company reported progress toward Phase 3 trials, supported by earlier Phase 2a follow-up data. An interesting angle is how RAP-219’s dual focus on epilepsy and bipolar mania, including a planned long-acting injectable, could broaden Rapport’s clinical opportunity set. We’ll now examine how this momentum in RAP-219, particularly its Phase 3 preparation, influences Rapport Therapeutics’...

Rapport Therapeutics, Inc. (NASDAQ:RAPP) is one of the 10 Stocks That Have the Potential to Rise 1000%. On May 21, 2026, BTIG raised the firm’s price target on Rapport Therapeutics, Inc. (NASDAQ:RAPP) to $65 from $53 and maintained a Buy rating on the shares. BTIG cited clinical execution behind its more constructive stance on RAP-219 […]

BOSTON and SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that management plans to participate in two upcoming investor conferences. Jefferies Global Healthcare Conference (New York City) – fireside chat on Wednesday, June 3, 2026, at 8:4

Phase 2a follow-up period data for RAP-219 in focal onset seizures (FOS) demonstrated sustained seizure reduction, including a 90% median reduction in clinical seizures over baseline in weeks 9-12 RAP-219 Phase 2 trial in bipolar mania topline results now expected in the fourth quarter of 2026, ahead of previous 1H 2027 guidance RAP-219 Phase 3 program in FOS remains on track for initiation in the second quarter of 2026 Pipeline programs, including RAP-219 long-acting injectable formulation, RAP

Over the last year, a good number of insiders have significantly increased their holdings in Rapport Therapeutics, Inc...